An announcement from Capricor Therapeutics ( (CAPR) ) is now available.
Capricor Therapeutics has struck a pivotal deal with Nippon Shinyaku for the European commercialization and distribution of their leading drug candidate, deramiocel, aimed at treating Duchenne muscular dystrophy. This collaboration could bring Capricor up to $715 million in milestone payments, plus a double-digit percentage of product revenue, bolstering their financial position and extending their operational runway into 2026. Additionally, Nippon Shinyaku will invest $15 million in Capricor stock at a 20% premium, showcasing strong confidence in the potential of deramiocel and Capricor’s future.
Find detailed analytics on CAPR stock on TipRanks’ Stock Analysis page.
